06
September 2019
iX Biopharma Ltd participated in SGX’s 20th anniversary celebrations by striking the SGX gong to open the Singapore securities market on 6 September 2019.
Read On23
August 2019
iX Biopharma Ltd. has reported results for the fourth financial quarter and financial year ended 30 June 2019
Read OnSublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.
Read OnThe Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine
Oxford Journal on Pain Medicine, 2017The absolute bioavailability of racemic ketamine from a novel sublingual formulation
British Journal of Clinical Pharmacology, 2013A Phase I Pharmacokinetic and Bioavailability Study of a Sublingual Fentanyl Wafer in Healthy Volunteers
Anesthesia and Analgesia, 20121 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com